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Background: Supplemental long-chain omega-3 (n–3) fatty acids (EPA and DHA) raise erythrocyte EPA + 
DHA [omega-3 index (O3I)] concentrations, but the magnitude or variability of this effect is unclear. 
Objective: The purpose of this study was to model the effects of supplemental EPA + DHA on the O3I. 
Methods: Deidentified data from 1422 individuals from 14 published n–3 intervention trials were included. 
Variables considered included dose, baseline O3I, sex, age, weight, height, chemical form [ethyl ester (EE) 
compared with triglyceride (TG)], and duration of treatment. The O3I was measured by the same method 
in all included studies. Variables were selected by stepwise regression using the Bayesian information 
criterion. 
Results: Individuals supplemented with EPA + DHA (n = 846) took a mean ± SD of 1983 ± 1297 mg/d, and 
the placebo controls (n = 576) took none. The mean duration of supplementation was 13.6 ± 6.0 wk. The 
O3I increased from 4.9% ± 1.7% to 8.1% ± 2.7% in the supplemented individuals ( P < 0.0001). The final 
model included dose, baseline O3I, and chemical formulation type (EE or TG), and these explained 62% of 
the variance in response (P < 0.0001). The model predicted that the final O3I (and 95% CI) for a population 
like this, with a baseline concentration of 4.9%, given 850 mg/d of EPA + DHA EE would be ∼6.5% (95% CI: 
6.3%, 6.7%). Gram for gram, TG-based supplements increased the O3I by about 1 percentage point more 
than EE products. 
Conclusions: Of the factors tested, only baseline O3I, dose, and chemical formulation were significant 
predictors of O3I response to supplementation. The model developed here can be used by researchers to 
help estimate the O3I response to a given EPA + DHA dose and chemical form. 
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ABSTRACT
Background: Supplemental long-chain omega-3 (n–3) fatty acids
(EPA and DHA) raise erythrocyte EPA + DHA [omega-3 index
(O3I)] concentrations, but the magnitude or variability of this effect
is unclear.
Objective: The purpose of this study was to model the effects of
supplemental EPA + DHA on the O3I.
Methods: Deidentified data from 1422 individuals from 14
published n–3 intervention trials were included. Variables considered
included dose, baseline O3I, sex, age, weight, height, chemical form
[ethyl ester (EE) compared with triglyceride (TG)], and duration of
treatment. The O3I was measured by the same method in all included
studies. Variables were selected by stepwise regression using the
Bayesian information criterion.
Results: Individuals supplemented with EPA + DHA (n = 846)
took a mean ± SD of 1983 ± 1297 mg/d, and the placebo controls
(n = 576) took none. The mean duration of supplementation
was 13.6 ± 6.0 wk. The O3I increased from 4.9% ± 1.7% to
8.1% ± 2.7% in the supplemented individuals ( P < 0.0001). The
final model included dose, baseline O3I, and chemical formulation
type (EE or TG), and these explained 62% of the variance in response
(P < 0.0001). The model predicted that the final O3I (and 95%
CI) for a population like this, with a baseline concentration of 4.9%,
given 850 mg/d of EPA + DHA EE would be ∼6.5% (95% CI: 6.3%,
6.7%). Gram for gram, TG-based supplements increased the O3I by
about 1 percentage point more than EE products.
Conclusions: Of the factors tested, only baseline O3I, dose, and
chemical formulation were significant predictors of O3I response
to supplementation. The model developed here can be used by
researchers to help estimate the O3I response to a given EPA + DHA
dose and chemical form. Am J Clin Nutr 2019;110:1034–1040.
Keywords: n–3 fatty acids, omega-3 index, dietary supplements,
EPA, DHA, statistical models
Introduction
The literature supporting the benefits of long-chain omega-
3 (n–3) fatty acids (LC n–3 FAs; i.e., EPA and DHA) in
cardiovascular disease (CVD) has been mixed (1). A 2018 meta-
analysis concluded that the current evidence did not support a
This report was self-funded by OmegaQuant Analytics, LLC, a commercial
laboratory providing fatty acid analytical services for researchers, health care
providers, and consumers.
Supplemental Tables 1 and 2 and Supplemental Materials are available
from the “Supplementary data” link in the online posting of the article and
from the same link in the online table of contents at https://academic.oup.
com/ajcn/.
Address correspondence to WSH (e-mail: bill@omegaquant.com).
Abbreviations used: BIC, Bayesian information criterion; CHD, coronary
heart disease; CVD, cardiovascular disease; EE, ethyl ester; FA, fatty acid;
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controlled trial; TG, triglyceride.
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role for n–3 fatty acids (FAs) in CVD risk reduction (2), but in 3
major randomized trials reported in late 2018, n–3 FA treatment
significantly reduced risk for vascular death (3), myocardial
infarction (4), and major adverse cardiovascular events (5). The
latter study was particularly compelling as it used 4 g EPA
(as opposed to the usual 0.84 g EPA + DHA) in statin-treated
patients and found a 25% risk reduction in CVD events. Hence,
some recent data support a role for n–3 FAs in reducing risk
for CVD.
One LC n–3 FA-based marker for which target concentrations
have been proposed is the erythrocyte membrane EPA + DHA
content [hereafter the omega-3 index (O3I)] (6). The O3I is
EPA+DHA expressed as a weight percentage of total FAs. It
has been shown to be a stable biomarker of dietary intake
and a valid surrogate of tissue LC n–3 FAs (7). However,
there is still large interperson variability in tissue incorporation
as it relates to intake (8). The O3I was first proposed as a
potential risk factor for coronary heart disease (CHD) death in
2004 (6), and subsequent cross-sectional as well as prospective
studies have supported its clinical utility for that purpose (9,
10). Analysis of these studies shows that an O3I of 8% or more
is protective against fatal CHD (11). The O3I is also inversely
correlated with major depressive disorders and inflammatory
biomarkers (12, 13).
Currently, there are no guidelines to help researchers determine
the LC n–3 FA dose needed to attain a specific O3I or to guide
clinicians in recommending LC n–3 FA doses for individual
patients. Several factors are known to alter an individual’s O3I
response to dose, the most important of which, after the dose
itself, appear to be body weight and baseline O3I (14, 15). Other
potential factors that could affect response to dose are sex (14,
16), age (14, 17), the chemical formulation of EPA and DHA (18,
19), genetic factors (20), smoking (21), dietary fat content of the
accompanying meal (22, 23), and possibly even choline intake
(24).
In a prior, single-center study, Flock et al. (14) developed
equations describing the dose-response relationship between
supplemental EPA + DHA and the O3I. In the present study,
we used individual-level data from Flock et al. (14) and 13
other intervention studies in which the O3I was measured
pre- and postdosing to determine which factors affect the
response of the O3I to supplementation with LC n–3 FAs. Using
basic demographic data along with baseline O3I values, we




Data from 1422 individuals from 14 published intervention
studies (14, 16, 25–36) in which EPA + DHA dietary supple-
ments or prescription products were given were used to predict
changes in the O3I (Table 1). All investigators provided data
on EPA and DHA dose, duration of supplementation, pre- and
post-O3I (both determined using the same laboratory method)
values from both placebo-treated and LC n–3 FA-treated subjects,
and standard demographic factors. Individual study sample sizes
ranged from 10 to 453, and a variety of participant types was
included. All studies were approved by local human subjects
research committees, and details can be found in each cited
publication.
Statistical analysis
We used paired t tests to compare the effects of treatment on
the O3I from baseline to end of treatment. Mixed-effects models
were used to predict changes in concentrations adjusting for
age, sex, race, BMI, and weight, and a random-effects term for
each study was fit separately for individuals taking supplements
compared with placebo. A significance level of 0.05 was used
for these analyses. All statistical analyses were performed in R,
version 3.5 (www.r-project.org).
To build a predictive model, we used the stepwise Bayesian
information criterion (BIC) to identify the best-fitting and most
parsimonious model (38). We considered 8 predictor variables for
absolute change in the O3I: EPA + DHA dose (in mg/d, including
both linear and quadratic terms), baseline O3I (including both
linear and quadratic terms), sex, age, BMI (including both linear
and quadratic terms), race (Asian, black, Hispanic, other, white),
duration of treatment (weeks, including both linear and quadratic
terms), and type of chemical formulation [ethyl ester (EE) or
triglyceride (TG)]. We also considered 3 potential statistical
interaction terms: baseline O3I and dose, dose and duration, and
formulation type and dose. Other factors that are known to affect
the O3I, such as whether the product was taken with a meal or
not (23), were not collected in these studies.
We performed the stepwise BIC approach in conjunction with
a 10-fold cross-validation. Specifically, we randomly broke the
entire data set into 10 equally sized, mutually exclusive subsets,
each containing ∼90% of the data (n ≈ 1280; the discovery
data sets). Each discovery data set then corresponded directly
to a validation data set (i.e., the remaining 10% of the data,
n ≈ 142 each). The stepwise BIC model-fitting approach was
performed on each of the 10 discovery data sets and validated on
the corresponding validation data set. The consensus final model
predictor variables and associated β estimates were obtained
by averaging across the estimates from the 10 validation data
sets. R2 was used to evaluate overall model predictive ability.
Furthermore, the unique contribution of each term in the model to
the overall R2 was evaluated by looking at change in R2 resulting
from adding the term to the model.
Results
Subject characteristics and overall change in the O3I
The average age, body weight, and BMI of the participants
was 56 years, 83 kg, and 28 kg/m2, respectively (Table 1). The
cohort was 74% male and 91% white. Treatment groups took
a mean of 1983 mg/d supplemental EPA + DHA (range: 254–
4400 mg/d), and placebo groups took 0 mg/d for a mean of
13.6 ± 6.0 wk (range: 4–24 wk). Compliance was reported in
7 of the 14 studies and averaged 95%. The O3I increased from
4.9% ± 1.7% to 8.1% ± 2.7% in the supplemented individuals
(n = 846; P < 0.0001; a 65% increase) and remained unchanged
in the placebo groups (from 5.0% ± 1.7% to 5.1% ± 1.7%;
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TABLE 2 Statistical model summary1
Characteristic Value
Average R2 (SD): discovery samples (10 samples of n = 1280 each) 0.59 (0.006)
Average R2 (SD): validation samples (10 samples of n = 142 each) 0.62 (0.05)
Variables included and significant in validation sample (unique R2)2 • Baseline O3I (quadratic) (0.04)
• Dose (mg/d) (quadratic) (0.16)3
• Type (0.01)
Model equation from validation samples4 Change in O3I = 2.60 + 0.921 ∗ TG − 0.842 ∗ Baseline O3I
+ 0.050 ∗ Baseline O3I2 + 0.0027 Dose
− (4.1 × 10−7) Dose2
1O3I, omega-3 index; TG, triglyceride.
2Unique R2 is calculated as the change in model R2 obtained when dropping the term but keeping all other terms in the model.
3There is high covariation between dose and type because the type variable has 3 groups [placebo, ethyl ester (EE), and TG], and so Dose = 0 is the
same as the placebo group. Baseline O3I values are entered as full integer, not as fraction or percentage. Dose is entered as mg/d. For type, enter “1” for TG
forms and “0” for EE forms. O3I = RBC EPA + DHA as a percentage of total fatty acids.
4The SDs of the 6 model coefficients across the 10 validation samples are 0.40, 0.17, 0.012, 0.12, 0.0004, and 9 × 10−8, respectively.
Modeling the O3I response to treatment
After development and validation following the 10-fold cross-
validation approach, the model included baseline O3I and
EPA + DHA dose, including quadratic terms for both variables,
and the chemical form (type) of EPA + DHA. This model
explained 62% of the variance. By comparing the R2 values with
and without each variable, we found that dose was uniquely
responsible for 80% of the explanatory ability (R2) followed by
baseline O3I (15%) and type of supplement (5%). Explained
variation was similar for discovery samples and validation
samples. Model coefficients, terms, and R2 (overall and unique
contribution) values are in Table 2, with additional details on the
model-building and cross-validation process in Supplemental
Tables 1 and 2.
The predicted change in the O3I (adjusted using the model)
was significantly higher for TG compared with EE forms (mean,
+0.89%; 95% CI: 0.63%, 1.15%). The equation was rearranged
to estimate the dose (separately for EE and TG forms) necessary
to attain an O3I of 8% as a function of the baseline O3I (Figure
1; see Supplemental Materials, Results). To confirm that this
model would also perform well for predicting the final O3I,
we compared the predicted with the observed final O3I values
(Figure 2). Observed values correlated with predicted values,
with an R2 of 0.69. To evaluate model robustness, we considered
1) weight (kg) instead of BMI, 2) dose/kg body weight instead
of dose, and 3) the ratio of EPA to DHA in the supplement. In
all cases, there was little effect on the final model (details not
shown).
Discussion
In this report, we developed a model to predict the effects
of LC n–3 FA supplementation on the O3I. The model had a
relatively high R2 value in both discovery and validation samples,
as well as between observed and predicted O3I values. In order
of importance, the major determinants of the O3I response were
dose, the baseline O3I, and type of supplement. The response was
not linear; therefore, some polynomial terms were needed to best
predict the response.
In addition to dose and the baseline O3I, which have been
previously reported to influence the O3I response to EPA + DHA
treatment (14, 15), supplement type also significantly affected
the response. TG formulations produced an ∼1 percentage point
greater increase in the O3I for the same EPA + DHA dose
than an EE formulation. Some (18, 19), but not all (31, 39,
40) studies have reported increased bioavailability of LC n–
3 FA in the TG compared with EE form. There also appears
to be a “food effect” for EPA + DHA (i.e., poorer absorption
in the absence of a fatty meal), which is considerably more
pronounced for the EE form than the TG (22, 23). Hence, a
lower response to EE compared with TG forms on the O3I might
be partly explained by this factor. Current evidence does not
support a major effect of FA desaturase gene variants on the
FIGURE 1 LC n-3 fatty acid doses needed to attain an RBC EPA + DHA
concentration (omega-3 index, or O3I in the equations) of 8% in ∼13 wk, as a
function of the baseline O3I. The model equations as estimated using the 10-
fold cross-validation approach described in the article with an n of 1422 were
rearranged to solve for the necessary dosage to attain a postsupplementation
O3I of 8%. The results are shown with separate lines for ethyl ester (EE) and
triglyceride (TG) supplements. The error bars reflect the 95% CIs.
The equation for TG is: Dose = 3292.68293 −
√
7.29 × 10−6+1.64 × 10−6(−4.479 + 0.158BaselineO3I+0.05Baseline O3I2 )
8.2 × 10−7 .
The equation for EE is: Dose = 3292.68293 −
√
7.29 × 10−6+1.64 × 10−6(−5.4 + 0.158BaselineO3I+0.05Baseline O3I2 )
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FIGURE 2 Predicted compared with observed RBC EPA + DHA concentration [omega-3 index (O3I)]. We used the model to calculate the predicted final
O3I, which was then compared with the observed O3I values (see equation at end of paragraph). When using the model for the entire data set ( n = 1422),
observed values correlated with predicted values, with an R2 of 0.69. Two lines are shown: the line y = x (thin dashed line) illustrates the line of “perfect
prediction,” and the heavy solid line represents the best-fit line of the predicted compared with observed O3I values (Actual O3I = 0.063 + 0.993 ∗ Predicted
O3I). In the equation for the best-fit line, the intercept (0.063; SE = 0.13) is not significantly different from 0 ( t test P = 0.62), and the slope (0.993; SE = 0.04)
is not significantly different from 1 (t test P = 0.69). The predicted O3I = baseline O3I + the predicted change in O3I, which is: 2.60 + 0.921 × 1 [if triglyceride
supplements were used; otherwise, × 0] – 0.842 × baseline O3I [entered as an integer, not a fraction or percentage] + 0.05 × (baseline O3I)2 + 0.0027 ×
dose [mg EPA + DHA/d] – 0.000000471 × dose2.
RBC FA response to n–3 FA supplementation (41). Surprisingly,
duration of supplementation did not enter the final model. This
probably reflects the fact that a majority of the changes in the
O3I occurred within 13–14 wk, which was the average duration
in this set of studies. This does not mean, however, that a new
steady state was established, since that takes somewhat longer to
achieve (42, 43).
Potential research uses of the model
The model equation developed herein can be used to estimate
the final O3I (and 95% CI) of a population given the LC n–3
FA dose and baseline O3I. As an example, a population with
a baseline O3I of 4.9% (like this pooled cohort) that is given
840 mg EPA + DHA/d (e.g., 1 n–3 acid ethyl ester capsule)
would achieve a mean O3I of ∼6.5% (95% CI: 6.3%, 6.7%).
Rearranging the equation, one can calculate the approximate
EPA + DHA doses (TG forms) to achieve a mean O3I of 8%
in 13 wk: 2200 mg/d for a baseline O3I of 2%, 1500 mg for a
4% baseline, and 750 mg for a 6% baseline (Figure 1). Using
this example, we predict that the minimum dose (i.e., the lower
bound of a 95% CI for the mean required dose) of EPA + DHA
necessary to be 95% certain that the mean baseline O3I of 4%
will increase to 8% (in 13 wk) is ∼1750 g/d of TG or 2500 g/d of
EE. The daily dose needed over a lifetime to achieve an O3I of
8% is likely much lower. For example, the average EPA + DHA
intake in Japan is “only” 800–1000 mg/d, and the mean O3I in
the Japanese is >8% (44).
A dose of about 2000 mg/d of EPA + DHA is much higher
than current recommended intakes to reduce CVD risk. The
2015–2020 Dietary Guidelines for Americans recommend 8 oz
of fish per week, which is said to be equivalent to about 250
mg/d EPA + DHA (45), and the American Heart Association
recommends 1–2 servings of “oily” fish per week (assumed to
approximate 500 mg/d EPA + DHA) to reduce CVD risk (46, 47).
Using the model and assuming the TG form, these EPA + DHA
intakes would increase the O3I from 4% to ∼6%. According
to National Health and Nutrition Examination Survey 2003–
2008 data, 90% of Americans do not meet the 500-mg/d intake
recommended by the Academy of Nutrition and Dietetics (48),
and 80% do not meet the 250-mg/d goal (46).
Several large randomized controlled trials (RCTs) of n–3 FAs
and CVD completed over the past decade have reported no
effects, and these have been summarized multiple times in meta-
analyses (2, 49). Only one of those trials directly measured the
O3I and only in a subset of subjects. In that study, the average
O3I increased from 4.8% to 6.7% after 3 mo. Only 23% of the
treated patients reached an O3I >8% (34). The model developed
herein predicted a final value of 6.5% for that study population.
In 2018, the highest-dose RCT of LC n–3 FAs with clinical
endpoints was reported. Bhatt et al. (50) used 4000 mg/d
icosapent ethyl (EPA EE) in a cohort of >8000 statin-treated
patients with hypertriglyceridemia. Major CVD events were
reduced by 25%. Effects on the O3I were not reported in this
study, and the equation derived here cannot be used to estimate
the effects on the O3I because only EPA was provided. Pure
EPA, while raising RBC EPA, also slightly lowers RBC DHA
concentrations (51), so the net effect on the O3I is difficult to
predict.
Strengths and limitations
A strength of the current study is that it included many diverse
data sets, which increases the generalizability of the model
since the studies included a variety of ages, dosages, chemical
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populations in 3 Western countries (United States, Italy, and
Norway). Interstudy variability was minimized by use of the same
laboratory method for the O3I. However, this analysis has several
limitations and potential confounders, as well. For example, only
one study directly (31) compared EE with TG LC n–3 FA forms,
so the magnitude of the differences in the O3I response to these
two forms should be considered tentative. Most studies used only
one dosage compared with placebo, with only four studies (14,
31, 35, 36) investigating multiple doses. In addition, most of
the cohorts were not racially diverse, with over 90% of subjects
being white, likely explaining why race did not enter the final
models. It is unknown how racial differences may affect the
O3I response to dose. Similarly, because 74% of this aggregated
cohort was male, the results may apply more robustly to men than
women. Also, due to limitations in the range of baseline O3Is in
these studies, the model works best for baseline values between
∼2% and 6%. Hence, the predicted values are not as accurate
for individuals who are already close to the target O3I of 8%.
This exercise also does not address the question of how much
EPA + DHA should be taken to maintain an O3I of 8% once
it is achieved. As noted earlier, the mean duration of treatment
was only 13.6 wk, and steady-state levels were probably not
achieved. The ratio of EPA to DHA in a given supplement
could affect RBC membrane incorporation of the sum (52),
but the narrow range of EPA/DHA ratios of the supplements
used in these studies caused this variable to not enter the final
model. Finally, no studies using krill oil (LC n–3 FA present
mostly in phospholipid forms) were available. A myriad of other
possible factors also could influence absorption and membrane
incorporation of LC n–3 FAs that were not considered in this
analysis, including fasted or fed state, the amount of fat taken
with the supplement, possible drug interactions, physical activity,
other background dietary factors (e.g., alcohol intake), physio-
logical state (e.g., pregnancy, lactation), genetic differences, and
dyslipidemia.
Conclusions
In order for 95% of subjects (not just 50%) to achieve
a desirable O3I from a baseline of ∼4%, roughly 2000 g/d
EPA + DHA (depending on the chemical form) would likely
be required. As noted, the equation developed here can aid in
predicting population O3I changes, but because of the large
interindividual variability in the O3I response to EPA + DHA
supplementation, it will likely be less useful in the clinical setting
where direct testing of the O3I would be the preferred approach
to assessing EPA + DHA status.
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